Benitec Biopharma Inc.

NasdaqCM BNTC

Benitec Biopharma Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024

Benitec Biopharma Inc. Cash and Short-Term Investments is NA for the quarter ending September 30, 2024. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqCM: BNTC

Benitec Biopharma Inc.

CEO	Dr. Jerel A. Banks M.D., Ph.D.
IPO Date	June 24, 2014
Location	United States
Headquarters	3940 Trust Way
Employees	16
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Key trends

Past 5 years